GSK and Flagship Pioneering partner in deal worth up to $7bn to discover medicines and vaccines

The companies aim to develop a portfolio of up to ten candidates

(July 31, 2024) | By Jen Brogan.

Bringing together GSK’s expertise in disease and development capability via Flagship’s ecosystem of bioplatform companies, the collaboration aims to develop a portfolio of up to ten future medicines and vaccines, beginning in respiratory and immunology, which will each be subject to an exclusive option by GSK for further clinical development.

As part of the deal, both companies will initially fund up to $150m upfront to support an exploration phase to identify the most promising concepts for further research and development utilising Flagship’s bioplatform companies, which will be eligible to receive up to $720m in upfront, development and commercial milestones from GSK, as well as preclinical funding for each acquired programme plus tiered royalties.